



FEP Medical Policy Manual

FEP 2.04.148 Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes (ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53)

Effective Policy Date: July 1, 2023

Original Policy Date: July 2020

Related Policies:

- 2.04.02 - Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)
- 2.04.08 - Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
- 2.04.101 - Genetic Testing for Li-Fraumeni Syndrome
- 2.04.44 - Genetic Testing for Familial Cutaneous Malignant Melanoma
- 2.04.93 - Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
- 2.04.99 - Genetic Testing for Hereditary Pancreatitis
- 5.21.52- Lynparza

Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes (ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53)

Description

Description

Pancreatic cancer is the fourth leading cause of cancer death in the United States, accounting for 7.8% of all cancer deaths in 2020. Multiple genetic syndromes are associated with an increased risk for pancreatic cancer, and approximately 10% to 15% of patients with pancreatic cancer are thought to have a hereditary susceptibility to the disease. Germline genetic testing for pancreatic cancer susceptibility genes is proposed to guide treatment decisions in patients with pancreatic cancer, and to inform decisions about surveillance in asymptomatic patients at high risk of pancreatic cancer.

OBJECTIVE

The objective of this evidence review is to evaluate the clinical validity and clinical utility of germline genetic testing of individuals with or at high-risk of pancreatic cancer and to determine if its use improves the net health outcome.

POLICY STATEMENT

Genetic testing for *BRCA1*, *BRCA2*, and *PALB2* variants to guide selection for treatment with platinum-based chemotherapy in previously untreated individuals with locally advanced or metastatic pancreatic cancer may be considered **medically necessary**.

Genetic testing for *BRCA1* and *BRCA2* variants to guide selection for treatment with olaparib (Lynparza) in individuals with pancreatic cancer may be considered **medically necessary**.

Genetic testing for *ATM*, *CDKN2A*, *EPCAM*, *MMR* genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*), *STK11*, and *TP53* in individuals with pancreatic cancer is considered **investigational** unless the individual meets criteria for testing as specified in another policy (see policy guidelines).

POLICY GUIDELINES

Related Policies on Hereditary Cancer Syndromes

- Genetic testing for BRCA1 and BRCA2 variants
 - 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
- Genetic testing for *ATM* and *PALB2* gene variants
 - Policy 2.04.126 Moderate Penetrance Variants Associated with Breast Cancer in Individuals at High Breast Cancer Risk
- Genetic testing for *EPCAM*, *MMR* (*MLH1*, *MSH2*, *MSH6*, *PMS2*), and *STK11* gene variants
 - Policy 2.04.08 Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
- Genetic testing for *CDKN2A* gene variants
 - Policy 2.04.044 Genetic Testing for Familial Cutaneous Malignant Melanoma
- Genetic testing for *TP53* gene variants
 - 2.04.101 Genetic Testing for Li-Fraumeni Syndrome
- Genetic cancer susceptibility panel testing
 - Policy 2.04.93 Genetic Cancer Susceptibility Panels Using Next-Generation Sequencing

Genetic Counseling

Experts recommend formal genetic counseling for individuals who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

FDA REGULATORY STATUS

Testing for variants associated with pancreatic cancer is typically done by direct sequence analysis or next-generation sequencing. A number of laboratories offer to test for the relevant genes, either individually or as panels.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Lab Test X is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

In December 2019, the FDA approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma, as detected by an FDA approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Also in 2019, BRACAnalysis CDx received expanded FDA approval for use as a companion diagnostic for Lynparza (olaparib) in pancreatic cancer patients.⁸

RATIONALE

Summary of Evidence

For individuals who have pancreatic cancer who receive testing for a *BRCA1*, *BRCA2*, or *PALB2* variant to guide selection for first-line treatment, the evidence includes observational studies. Multiple observational studies have demonstrated that testing patients with pancreatic cancer can identify individuals with *BRCA1*, *BRCA2*, and *PALB2* variants, including among those who do not have a family history of pancreatic cancer. Observational studies have reported a survival advantage when patients with a BRCA or PALB2 variant were treated with platinum-based chemotherapy regimens compared to non-platinum-based regimens. Although these studies are limited by their small sample sizes and retrospective designs, the consistency and magnitude of benefit across studies suggests that genetic testing for these variants to aid in treatments decisions is a reasonable approach. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have pancreatic cancer who receive testing for a *BRCA1* or *BRCA2* variant to guide selection for targeted treatment, the evidence includes observational studies and 1 randomized controlled trial. Multiple observational studies have demonstrated that testing patients with pancreatic cancer can identify individuals with *BRCA1* or *BRCA2* variants, including among those who do not have a family history of pancreatic cancer. A placebo-controlled trial of olaparib as maintenance therapy in patients with germline *BRCA1* or *BRCA2* variants and metastatic pancreatic cancer found longer progression-free survival with olaparib (7.4 months vs. 3.8 months; hazard ratio, 0.53; 95% confidence interval 0.35 to 0.82; $p=0.04$). The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with pancreatic cancer who receive genetic testing for *ATM*, *CDK2NA*, *EPCAM*, *MMR* genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*), *STK11*, and *TP53* to guide treatment, the evidence includes observational studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and test validity. Multiple observational studies have demonstrated that testing patients with pancreatic cancer can identify individuals with disease-associated variants, including among those who do not have a family history of the disease. However, there is no direct evidence comparing health outcomes in patients tested or not tested for a variant. Additionally, there are no targeted treatments for pancreatic cancer based on these genes, and management changes that would result from testing these genes are unclear. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Gastroenterology

In 2015, the American College of Gastroenterology Clinical Guideline on Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes includes the following recommendations on genetic testing for pancreatic cancer:⁷

- Individuals should be considered to be at risk for familial pancreatic adenocarcinoma if they (i) have a known genetic syndrome associated with pancreatic cancer, including hereditary breast-ovarian cancer syndrome, familial atypical multiple melanoma, and mole syndrome, PJS, LS, or other gene mutations associated with an increased risk of pancreatic adenocarcinoma; or (ii) have 2 relatives with pancreatic adenocarcinoma, where 1 is a first-degree relative; (iii) have 3 or more relatives with pancreatic cancer; or (iv) have a history of hereditary pancreatitis.
- Genetic testing of patients with suspected familial pancreatic cancer should include analysis of BRCA1/2, CDKN2A, PALB2, and ATM. Evaluation for PJS, LS, and hereditary pancreatitis-associated genes should be considered if other component personal and/or family history criteria are met for the syndrome.

American Society of Clinical Oncology

In 2019, an American Society of Clinical Oncology (ASCO) opinion statement addressed the identification and management of patients and family members with a possible predisposition to pancreatic adenocarcinoma and made the following recommendations:²

- PCO 1.2 Individuals with a family history of pancreatic cancer affecting 2 first-degree relatives meet the criteria for familial pancreatic cancer. Individuals whose family history meets criteria for familial pancreatic cancer, those with 3 or more diagnoses of pancreatic cancer in the same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing (Type: informal consensus; benefits outweigh harms; Strength of statement: strong).
- PCO 1.3 Genetic risk evaluation should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer syndromes to determine the most appropriate testing strategy and discuss implications of the findings for family members. Germline genetic testing for patients with pancreatic cancer should be offered in the context of shared decision making. (Type: informal consensus; benefits outweigh harms; Strength of statement: strong).
- PCO 2.1 All patients diagnosed with pancreatic adenocarcinoma should undergo an assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk includes obtaining a personal cancer history and family history of cancers in first- and second-degree relatives. However, recent data demonstrate that many individuals who develop pancreatic cancer in the setting of genetic predisposition lack clinical features or family cancer history typically associated with the corresponding hereditary syndrome. Therefore, germline genetic testing may be discussed with patients with a personal history of pancreatic cancer, even if family history is unremarkable (Type: informal consensus; benefits outweigh harms; Strength of statement: strong).

In 2020, ASCO published a guideline update on recommendations for second-line therapy options for metastatic pancreatic cancer.²⁴ In patients who have a germline BRCA1 or BRCA2 mutation and who have received first-line platinum based chemotherapy without disease progression for at least 16 weeks, options for continued treatment include chemotherapy or the PARP inhibitor olaparib.

International Cancer of the Pancreas Screening Consortium

In 2020, the International Cancer of the Pancreas Screening Consortium published an updated consensus document on the management of patients with increased risk for familial pancreatic cancer.²⁵ The panel recommended pancreatic cancer surveillance performed in a research setting for the following individuals:

- All patients with Peutz-Jeghers syndrome (carriers of a germline *LKB1/STK11* gene mutation)
- All carriers of a germline *CDKN2A* mutation
- Carriers of a germline *BRCA2*, *BRCA1*, *PALB2*, *ATM*, *MLH1*, *MSH2*, or *MSH6* gene mutation with at least 1 affected first-degree blood relative
- Individuals who have at least 1 first-degree relative with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer (familial pancreatic cancer kindred)

The preferred surveillance tests are endoscopic ultrasound and magnetic resonance imaging (MRI). The recommended age to initiate surveillance depends on an individual's gene mutation status and family history, but no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer. There was no consensus on the age to end surveillance.

National Comprehensive Cancer Network

Two National Comprehensive Cancer Network (NCCN) guidelines address germline genetic testing in individuals with or at high risk for pancreatic cancer.^{26,6}

The Guidelines on Genetic/Familial High-risk Assessment: Breast, Ovarian, and Pancreatic (v.1.2023) recommend germline testing for all individuals with exocrine pancreatic cancer, and specify that testing of first-degree relatives should only be done only if it is impossible to test the individual who has pancreatic cancer.²⁶

The Guideline on Treatment of Pancreatic Adenocarcinoma (v.2.2022) recommends germline testing for any patient with confirmed pancreatic cancer using comprehensive gene panels for hereditary cancer syndromes.⁶ The guideline specifies the following genes as those typically tested for pancreatic cancer risk: ATM, BRCA1, BRCA2, CDKN2A, most Lynch syndrome genes (MLH1, MSH2, MSH6, EPCAM), PALB2, STK11, and TP53. For patients with locally advanced disease, preferred first-line therapy regimens include gemcitabine + cisplatin for patients with BRCA1/2 or PALB2 variants For patients with metastatic disease who have received previous platinum-based chemotherapy, olaparib is preferred only for patients with germline BRCA 1/2 variants.

Genetic counseling is recommended for patients who test positive for a pathogenic variant, or for patients with a positive family history of pancreatic cancer, regardless of test results. The guidelines also recommend genetic counseling for patients who test positive for a pathogenic variant or for patients with a positive family history of pancreatic cancer, regardless of variant status.

U.S. Preventive Services Task Force Recommendation

The 2019 U.S. Preventive Services Task Force recommendation on screening for pancreatic cancer applies to asymptomatic adults not known to be at high-risk of pancreatic cancer.⁵ The recommendation does not apply to persons at high-risk of pancreatic cancer due to an inherited genetic syndrome or due to a history of hereditary pancreatic cancer.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. NIH National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Pancreatic Cancer. <https://seer.cancer.gov/statfacts/html/pancreas.html>. Accessed January 6, 2023.
2. Stoffel EM, McKernin SE, Khorana AA. Evaluating Susceptibility to Pancreatic Cancer: ASCO Clinical Practice Provisional Clinical Opinion Summary. *J Oncol Pract*. Feb 2019; 15(2): 108-111. PMID 30589608
3. O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. *J Clin Oncol*. May 01 2020; 38(13): 1378-1388. PMID 31976786
4. Reiss KA, Yu S, Judy R, et al. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. *JCO Precision Oncology*. Published online January 19, 2018. DOI: 10.1200/PO.17.00152.
5. Owens DK, Davidson KW, Krist AH, et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. Aug 06 2019; 322(5): 438-444. PMID 31386141
6. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed January 6, 2023.
7. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. Feb 2015; 110(2): 223-62; quiz 263. PMID 25645574
8. Food & Drug Administration. Premarket Approval: BRACAnalysis CDx. 2019. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020S019>. Accessed January 6, 2023.
9. Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. *Br J Cancer*. Sep 09 2014; 111(6): 1132-8. PMID 25072261
10. Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. *Br J Cancer*. Feb 2020; 122(3): 333-339. PMID 31787751
11. Yu S, Agarwal P, Mamtani R, et al. Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a Germline BRCA or PALB2 mutation. *JCO Precision Oncol*. Published online March 28, 2019. DOI: 10.1200/PO.18.00271

12. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer. *N Engl J Med.* Jul 25 2019; 381(4): 317-327. PMID 31157963
13. Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. *JAMA.* Jun 19 2018; 319(23): 2401-2409. PMID 29922827
14. Shindo K, Yu J, Suenaga M, et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. *J Clin Oncol.* Oct 20 2017; 35(30): 3382-3390. PMID 28767289
15. Brand R, Borazanci E, Speare V, et al. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. *Cancer.* Sep 01 2018; 124(17): 3520-3527. PMID 30067863
16. Mandelker D, Zhang L, Kemei Y, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. *JAMA.* Sep 05 2017; 318(9): 825-835. PMID 28873162
17. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. *Gastroenterology.* Mar 2015; 148(3): 556-64. PMID 25479140
18. Abe T, Blackford AL, Tamura K, et al. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. *J Clin Oncol.* May 01 2019; 37(13): 1070-1080. PMID 30883245
19. Canto MI, Almario JA, Schulick RD, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. *Gastroenterology.* Sep 2018; 155(3): 740-751.e2. PMID 29803839
20. Vasen H, Ibrahim I, Ponce CG, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. *J Clin Oncol.* Jun 10 2016; 34(17): 2010-9. PMID 27114589
21. Konings ICAW, Canto MI, Almario JA, et al. Surveillance for pancreatic cancer in high-risk individuals. *BJS Open.* Oct 2019; 3(5): 656-665. PMID 31592073
22. Dbouk M, Katona BW, Brand RE, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. *J Clin Oncol.* Oct 01 2022; 40(28): 3257-3266. PMID 35704792
23. Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. *Gut.* Jun 2022; 71(6): 1152-1160. PMID 33820756
24. Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. *J Clin Oncol.* Aug 05 2020: JCO2001364. PMID 32755482
25. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. *Gut.* Jan 2020; 69(1): 7-17. PMID 31672839
26. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed January 5, 2023.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
June 2020	New policy	Policy created with literature review through August 26, 2019. Genetic testing for BRCA1 and BRCA2 variants in patients with pancreatic cancer may be considered medically necessary. Genetic testing for other genes in patients with pancreatic cancer is considered investigational unless the individual meets testing criteria specified in another policy.
June 2021	Replace policy	Policy updated with literature review through December 16, 2020; references added. New indication and medically necessary statement added for BRCA1, BRCA2, and PALB2 variant testing to select first-line treatment with platinum chemotherapy. PALB2 testing removed from indication 3. Title changed to "Germline Genetic Testing for Pancreatic Cancer Susceptibility Genes."
June 2022	Replace policy	Policy updated with literature review through January 3, 2022; no references added. Policy statements unchanged.
June 2023	Replace policy	Policy updated with literature review through January 6, 2023; references added. Minor editorial refinements to policy statements; intent unchanged. Policy title changed to include gene names (ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53).

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.